Rick Klausner
North America, California, United States
Description
Rick Klausner is a Chief Executive Officer at Lyell Immunopharma.
Investor Profile
Rick Klausner has made 4 investments, with 0 in the past 12 months and 75% as lead.
Stage Focus
- Series A (50%)
- Convertible Note (25%)
- Series B (25%)
Country Focus
- Israel (25%)
- United Kingdom (25%)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
- United States (25%)
- The Netherlands (25%)
Industry Focus
- Health Care
- Biotechnology
- Apps
- Artificial Intelligence (Ai)
- Internet
- Mobile
- Mobile Apps
- Software
- Web Development
- Commercial
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
'/%3e%3cuse xlink:href='%23a' transform='rotate(144 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(216 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(288 450 300)'/%3e%3c/svg%3e)
